UCART-22 is a gene-modified cell therapy commercialized by Cellectis, with a leading Phase II program in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of UCART-22’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for UCART-22 is expected to reach an annual total of $19 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
UCART-22 Overview
UCART-22 is under development for the treatment of relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma (B-NHL). The drug candidate is an allogeneic gene-edited T-cell product candidate. It is an immunotherapy comprising of CAR T cells and acts by targeting CD22. It was also under development for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). It is administered through intravenous route.
Cellectis Overview
Cellectis, operates as a clinical-stage biopharmaceutical company. It carries out research, develop and commercialize gene editing technology. The company’s pipeline products include UCART22, UCART123, UCART20x22, ALLO-501A 1, ALLO-715 3, ALLO-605 3, ALLO-316 4. z Its pipeline candidates treat Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Large B-cell Lymphoma, Multiple Myeloma, Multiple Myeloma, Renal Cell Carcinoma. Cellectis’s pioneer, deploying core proprietary technologies to develop off-the-shelf immunotherapies to target and eradicate cancer cells. It works in partnership with Allogene Therapeutics, Servier, Iovance Biotherapeutics, Inc, Cytovia Therapeutics, Inc., It operates in New York and Paris. Cellectis is headquartered in Paris, France.
For a complete picture of UCART-22’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.